Frailty profile precluding full-dose ABVD or A+AVD in classical Hodgkin lymphoma: ECOG ≥3...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-CHL-FRAILTY-AGE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-CHL |
| Sources | SRC-ESMO-HODGKIN-2024 SRC-NCCN-BCELL-2025 |
Red Flag Origin
| Definition | Frailty profile precluding full-dose ABVD or A+AVD in classical Hodgkin lymphoma: ECOG ≥3, OR (age ≥60 with ≥2 comorbidities — elderly cHL has worse outcomes regardless of regimen), OR composite frailty (age ≥75 + Charlson ≥3 + albumin <3.5). Triggers de-escalation to AVD (omit bleomycin), VEPEMB (gem-vinorelbine-based), or BV-AVD. |
|---|---|
| Clinical direction | de-escalate |
| Category | frailty-age |
Trigger Logic
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 3
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 60
},
{
"comparator": ">=",
"finding": "comorbidity_count",
"threshold": 2
}
]
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 75
},
{
"comparator": ">=",
"finding": "charlson_score",
"threshold": 3
},
{
"comparator": "<",
"finding": "albumin_g_dl",
"threshold": 3.5
}
]
}
],
"type": "composite_score"
}
Notes
Elderly cHL (>60y) outcomes substantially worse — bleomycin pulmonary toxicity disproportionately high (>20% pneumonitis with BLEO in age ≥60 per German Hodgkin trials); omit bleomycin or use BV substitution (A+AVD per ECHELON-1 elderly subgroup — favorable PFS without bleo pneumonitis). Frail / unfit: VEPEMB or BV-bendamustine combinations (palliative-curative balance). BEACOPP-escalated contraindicated >60y due to TRM. CGA-guided dose adjustment essential.
Used By
Algorithms
ALGO-CHL-2L- ALGO-CHL-2L